Skip to main content

About Genvor

Pioneering the Future of Plant Health and Human Wellness

Genvor develops advanced peptide solutions to boost yields, cut chemical use, and secure a sustainable food future, while bringing science-backed peptide innovation to human health and wellness.

Jaynes Yates

The Genvor Origin

Where Agriculture Meets Human Health

Jaynes
Yates

Dr. Jesse Jaynes, one of the world's leading authorities on therapeutic peptide design, had spent over four decades engineering synthetic peptides across agriculture, animal health, wound healing, and oncology. His foundational work demonstrated that engineered peptides could target pathogens with precision and safety across biological systems — from protecting crops against fungal disease to activating the human immune system against cancer cells.

Dr. Clayton Yates, a molecular pathologist and cancer researcher recognized among the 100 Most Inspiring Black Scientists in America, had spent his career studying how peptides interact with human biology at the cellular level. His expertise in human peptide therapeutics, immune response, and cellular signaling brought a deep understanding of how peptides perform inside the human body.

Together, they saw what others missed: a single AI-accelerated platform could design peptides optimized for any biological system — plant or human.

In 2018, they founded Genvor with a bold vision: engineer peptides that optimize outcomes across agriculture and human health, using AI to accelerate discovery beyond what traditional R&D could achieve alone.

If the same platform that designs peptides to protect crops from disease could also design peptides for human recovery, performance, and daily wellness — with the same precision, safety, and efficacy — then one technology core could serve two massive markets.

Our Leadership Team

Loading...

Milestones in Our Journey

What began as a mission to reimagine crop protection has grown into a dual-market platform spanning agriculture and human health. Today, Genvor partners with Tier-1 agricultural leaders through a capital-efficient licensing model while developing its first consumer peptide programs for recovery, performance, anti-aging, and daily wellness.

2024
Launch of first corn AMP trait for commercial licensing.
2024
Awarded Bayer’s Golden Ticket, gaining access to lab space, mentorship, and commercialization resources.
2024
Chad Pawlak appointed CEO and elected to Board of Directors.
2023
Genvor lists on OTC:QB under symbol GNVR.
2021
Second U.S. patent expands peptide applications for transgenic crops.
2018
Genvor founded; entered CRADA with USDA; patented transgenic corn with peptide AGM182.
1998
The synthetic antimicrobial peptide D4E1, developed by Dr. Jaynes in collaboration with research partners, is made publicly available as a biological control tool.
1984
Dr. Jaynes develops a comprehensive phenotype system encompassing all amino acids—laying the groundwork for a proprietary design platform that continues to evolve today.
1978
The foundation of our technology traces back more than four decades to groundbreaking academic research and early peptide development in agriculture.

Let’s Build the Future Together

Genvor partners across agriculture and human health & wellness. Our licensing-first model and DTC wellness strategy are built for real-world deployment and long-term success.

Interested in partnering across agriculture or health & wellness? Let’s talk.

Email: licensing@genvor.com
Phone: (715)-903-6473